Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice

Rimas V. Lukas, Maciej Mrugala

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.

Original languageEnglish (US)
Pages (from-to)209-219
Number of pages11
JournalNeuro-Oncology Practice
Volume4
Issue number4
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Glioma
temozolomide
Brain Neoplasms
Lomustine
Procarbazine
Carmustine
Vincristine
Therapeutics
Guidelines
Neoplasms
Bevacizumab
Clinical Decision-Making

Keywords

  • Bevacizumab
  • Glioma
  • Lomustine
  • Temozolomide
  • Tumor treating fields

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. / Lukas, Rimas V.; Mrugala, Maciej.

In: Neuro-Oncology Practice, Vol. 4, No. 4, 01.12.2017, p. 209-219.

Research output: Contribution to journalArticle

@article{9e3b2ae063ac4b45abd7c0e221ba806e,
title = "Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice",
abstract = "The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.",
keywords = "Bevacizumab, Glioma, Lomustine, Temozolomide, Tumor treating fields",
author = "Lukas, {Rimas V.} and Maciej Mrugala",
year = "2017",
month = "12",
day = "1",
doi = "10.1093/nop/npw016",
language = "English (US)",
volume = "4",
pages = "209--219",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice

AU - Lukas, Rimas V.

AU - Mrugala, Maciej

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.

AB - The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.

KW - Bevacizumab

KW - Glioma

KW - Lomustine

KW - Temozolomide

KW - Tumor treating fields

UR - http://www.scopus.com/inward/record.url?scp=85044068647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044068647&partnerID=8YFLogxK

U2 - 10.1093/nop/npw016

DO - 10.1093/nop/npw016

M3 - Article

AN - SCOPUS:85044068647

VL - 4

SP - 209

EP - 219

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 4

ER -